Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry

被引:6
|
作者
Andrade, Joao A. de [1 ]
Kulkarni, Tejaswini [2 ]
Neely, Megan L. [3 ,4 ]
Hellkamp, Anne S. [3 ,4 ]
Case, Amy Hajari [5 ]
Guntupalli, Kalpalatha [6 ]
Bender, Shaun [7 ]
Conoscenti, Craig S. [7 ]
Snyder, Laurie D. [3 ,4 ]
机构
[1] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] Duke Clin Res Inst, Durham, NC USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Piedmont Healthcare, Atlanta, GA USA
[6] Baylor Coll Med, Houston, TX 77030 USA
[7] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
关键词
Lung disease; Interstitial pulmonary fibrosis; Guideline; Hospitalization; Mortality; INTERSTITIAL LUNG-DISEASE; CLINICAL-PRACTICE; OXYGEN-THERAPY; ANTACID THERAPY; PERCEPTIONS; SPUTUM; INDEX; COUGH; EQ-5D;
D O I
10.1016/j.rmed.2021.106637
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Few data are available on the extent to which clinical practice is aligned with international guidelines for the management of idiopathic pulmonary fibrosis (IPF). We investigated the extent to which management guidelines for IPF have been implemented in the US IPF-PRO Registry and associations between implementation of guidelines and clinical outcomes. Methods: We assessed the implementation of eight recommendations in clinical practice guidelines within the 6 months after enrollment: visit to a specialized clinic; pulmonary function testing; use of oxygen in patients with resting hypoxemia and exercise-induced hypoxemia; referral for pulmonary rehabilitation; treatment of gastroesophageal reflux disease; initiation of anti-fibrotic therapy; referral for lung transplant evaluation. An implementation score was calculated as the number of recommendations achieved divided by the number for which the patient was eligible. Associations between implementation score and outcomes were analyzed using logistic regression and Cox proportional hazards models. Results: Among 727 patients, median (Q1, Q3) implementation score was 0.6 (0.5, 0.8). Patients with an implementation score >0.6 had greater disease severity than those with a lower score. Implementation was lowest for referral for pulmonary rehabilitation (19.5%) and lung transplant evaluation (22.3%). In unadjusted models, patients with higher implementation scores had a greater risk of death, death or lung transplant, and hospitalization, but no significant associations were observed in adjusted models. Conclusions: Management guidelines were more likely to be implemented in patients with IPF with greater disease severity. When adjusted for disease severity, no association was found between implementation of management guidelines and clinical outcomes.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Frequency and impact on clinical outcomes of sarcopenia in patients with idiopathic pulmonary fibrosis
    Fujita, Kohei
    Ohkubo, Hirotsugu
    Nakano, Akiko
    Mori, Yuta
    Fukumitsu, Kensuke
    Fukuda, Satoshi
    Kanemitsu, Yoshihiro
    Uemura, Takehiro
    Tajiri, Tomoko
    Maeno, Ken
    Ito, Yutaka
    Oguri, Tetsuya
    Ozawa, Yoshiyuki
    Murase, Takayuki
    Niimi, Akio
    CHRONIC RESPIRATORY DISEASE, 2022, 19
  • [42] Analyses of the relationship between ΔFVC, extent of fibrosis and extent of emphysema in patients with idiopathic pulmonary fibrosis (IPF)
    Cottin, Vincent
    Hansell, David M.
    Sverzellati, Nicola
    Weycker, Derek
    Antoniou, Katerina M.
    Atwood, Mark
    Oster, Gerry
    Kirchgaessler, Klaus-Uwe
    Wells, Athol U.
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [43] Clustering-aided prediction of outcomes in patients with idiopathic pulmonary fibrosis
    Wang, Lijun
    Wu, Peitao
    Liu, Yi
    Patel, Divya C.
    Leonard, Thomas B.
    Zhao, Hongyu
    RESPIRATORY RESEARCH, 2024, 25 (01)
  • [44] Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
    Kelly, Bryan T.
    Thao, Viengneesee
    Dempsey, Timothy M.
    Sangaralingham, Lindsey R.
    Payne, Stephanie R.
    Teague, Taylor T.
    Moua, Teng
    Shah, Nilay D.
    Limper, Andrew H.
    BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [45] The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
    Valeyre, Dominique
    Albera, Carlo
    Bradford, Williamson
    Costabel, Ulrich
    King, Talmadge
    Noble, Paul
    Sahn, Steven
    du Bois, Roland
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [46] Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
    Wuyts, Wim A.
    Dahlqvist, Caroline
    Slabbynck, Hans
    Schlesser, Marc
    Gusbin, Natacha
    Compere, Christophe
    Maddens, Sofie
    Lee, Yuan-Chi
    Kirchgaessler, Klaus-Uwe
    Bartley, Karen
    Bondue, Benjamin
    RESPIRATORY RESEARCH, 2019, 20 (01)
  • [47] Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons
    Nathan, Steven D.
    Wanger, Jack
    Zibrak, Joseph D.
    Wencel, Mark L.
    Burg, Cindy
    Stauffer, John L.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (02) : 175 - 181
  • [48] Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone
    Korfei, Martina
    Skwarna, Sylwia
    Henneke, Ingrid
    Klymenko, Oleksiy
    Dahlem, Gabriele
    Ziegler, Susanna
    von der Beck, Daniel
    Klepetko, Walter
    Fink, Ludger
    Seeger, Werner
    Kramer, Oliver
    Guenther, Andreas
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [49] Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
    Kreuter, Michael
    Bonella, Francesco
    Maher, Toby M.
    Costabel, Ulrich
    Spagnolo, Paolo
    Weycker, Derek
    Kirchgaessler, Klaus-Uwe
    Kolb, Martin
    THORAX, 2017, 72 (02) : 148 - 153
  • [50] EVALUATING THE CONSISTENCY WITH GUIDELINE RECOMMENDATIONS FOR DIAGNOSIS AND MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS IN NON-ACADEMIC SETTINGS
    Luckhardt, Tracy
    Sonavane, Sushilkumar
    Kulkarni, Tejaswini
    Lara, Maria del Pilar Acosta
    Gulati, Swati
    Il-Kim, Young
    Ramachandran, Rekha
    O'Beirne, Ronan
    de Andrade, Joao A.
    Crowe, D. Ralph
    SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023, 40 (01)